Search Results - "Coupal, Louis"

Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry by Choquette, Denis, Bessette, Louis, Alemao, Evo, Haraoui, Boulos, Postema, Roelien, Raynauld, Jean-Pierre, Coupal, Louis

“…Treatment persistence is an important consideration when selecting a therapy for chronic conditions such as rheumatoid arthritis (RA). We assessed the…”
Get full text

Discontinuation of tofacitinib and TNF inhibitors in patients with rheumatoid arthritis: analysis of pooled data from two registries in Canada by Movahedi, Mohammad, Choquette, Denis, Coupal, Louis, Cesta, Angela, Li, Xiuying, Keystone, Edward C, Bombardier, Claire, Investigators, OBRI

“…ObjectivesThe similarity in retention of tumour necrosis factor inhibitors (TNFi) and tofacitinib (TOFA) was previously reported separately by the Ontario Best…”
Get full text

Bayesian estimation of disease prevalence and the parameters of diagnostic tests in the absence of a gold standard by Joseph, L, Gyorkos, T W, Coupal, L

“…It is common in population screening surveys or in the investigation of new diagnostic tests to have results from one or more tests investigating the same…”
Get more information

Estimating the Benefits of Patient and Physician Adherence to Cardiovascular Prevention Guidelines: The MyHealthCheckup Survey by Grover, Steven, MD, MPA, FRCPC, Coupal, Louis, MSc, Kouache, Mohammed, MSc, Lowensteyn, Ilka, PhD, Marchand, Sylvie, RN, Campbell, Norman, MD, FRCPC

“…Abstract Background The management of cardiovascular risk factors such as hypertension and dyslipidemia is poorly described in many communities, and the…”
Get full text

Preventing cardiovascular disease among Canadians: Is the treatment of hypertension or dyslipidemia cost-effective? by Grover, Steven, MD MPA FRCPC, Coupal, Louis, MSc, Lowensteyn, Ilka, PhD

“…Background and objectives The direct health care costs associated with treating hypertension and dyslipidemia continue to grow in most western countries,…”
Get full text

How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease? by GROVER, Steven A, ALEXANDER, Charles M, COUPAL, Louis, WEISS, Thomas W, ZOWALL, Hanna, GOMES, Daniel R. J

“…How Cost-Effective Is the Treatment of Dyslipidemia in Patients With Diabetes but Without Cardiovascular Disease? Steven A. Grover , MD, MPA, FRCPC , Louis…”
Get full text

Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia? by Grover, Steven A., MD MPA FRCPC, Coupal, Louis, MSc, Kaouache, Mohammed, MSc, Lowensteyn, Ilka, PhD

“…Background Treatments for hypertension and dyslipidemia to prevent the development of cardiovascular disease compete for the same finite number of health care…”
Get full text

Determining the cost-effectiveness of preventing cardiovascular disease: Are estimates calculated over the duration of a clinical trial adequate? by Grover, Steven A., MD MPA FRCPC, Coupal, Louis, MSc, Lowensteyn, Ilka, PhD

“…Background Economic analyses of randomized clinical trials often focus only on the results that are observed during the study. However, for many preventive…”
Get full text

A Real-World Analysis on Weather Variation Disease Activity and Patient Reported Outcomes in Psoriatic Arthritis by Joly-Chevrier, Maxine, Coupal, Louis, Sauvageau, Loïc Choquette, Movahedi, Mohammad, Choquette, Denis

“…Anecdotally, patients with inflammatory articular diseases (IAD) such as psoriatic arthritis (PsA) report weather changes in their symptoms. The objective is…”
Get full text

Cost-utility analysis of second-line therapy with rituximab compared to tumour necrosis factor inhibitors in rheumatoid arthritis by Lopatina, Elena, Marshall, Deborah A., Coupal, Louis, Le Lorier, Jacques, Choquette, Denis

“…To compare direct costs and treatment utility associated with the second-line therapy with rituximab and tumour necrosis factor inhibitors (TNFis) (adalimumab,…”
Get full text

Development and clinical validation of an in situ biopsy-based multimarker assay for risk stratification in prostate cancer by Blume-Jensen, Peter, Berman, David M, Rimm, David L, Shipitsin, Michail, Putzi, Mathew, Nifong, Thomas P, Small, Clayton, Choudhury, Sibgat, Capela, Teresa, Coupal, Louis, Ernst, Christina, Hurley, Aeron, Kaprelyants, Alex, Chang, Hua, Giladi, Eldar, Nardone, Julie, Dunyak, James, Loda, Massimo, Klein, Eric A, Magi-Galluzzi, Cristina, Latour, Mathieu, Epstein, Jonathan I, Kantoff, Philip, Saad, Fred

“…Prostate cancer aggressiveness and appropriate therapy are routinely determined following biopsy sampling. Current clinical and pathologic parameters are…”
Get full text

Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA) by Gladman, Dafna D., Chandran, Vinod, Rosen, Cheryl F., Rohekar, Sherry, Boyd, Tristan, Eder, Lihi, Rahman, Proton, Dutz, Jan, Chan, Jonathan, Haydey, Richard P., Barac, Snezana, Laliberté, Marie-Claude, Girard, Tanya, Fournier, Pierre-André, Sutton, Mitchell, Pereira, Daniel, Chim, Tina, Coupal, Louis, Choquette, Denis

“…Objective Although patient outcomes in psoriatic arthritis (PsA) have improved with the advent of advanced therapies, there remains a high unmet need to treat…”
Get full text

Which advanced treatment should be used following the failure of a first-line anti-TNF in patients with rheumatoid arthritis? 15 years of evidence from the Quebec registry RHUMADATA by Choquette, Denis, Haraoui, Boulos, Movahedi, Mohammad, Bessette, Louis, Sauvageau, Loïc Choquette, Ferdinand, Isabelle, Joly-Chevrier, Maxine, Masetto, Ariel, Massicotte, Frédéric, Nadon, Valérie, Pelletier, Jean-Pierre, Raynauld, Jean-Pierre, Sauvageau, Diane, Villeneuve, Édith, Coupal, Louis

“…Since 2000, advanced therapies (AT) have revolutionized the treatment of moderate to severe rheumatoid arthritis (RA). Randomized control trials as well as…”
Get full text

Hypomagnesemia During Teriparatide Treatment in Osteoporosis: Incidence and Determinants by Bégin, Marie‐Josée, Ste‐Marie, Louis‐Georges, Coupal, Louis, Ethier, Jean, Räkel, Agnès

“…ABSTRACT In our clinical experience, we have encountered patients who developed hypomagnesemia after the introduction of teriparatide. Some trials have…”
Get full text

Heterogeneity in Patient Characteristics and Differences in Treatment Across 4 Canadian Rheumatoid Arthritis Cohorts by Hazlewood, Glen S, Bombardier, Claire, Li, Xiuying, Movahedi, Mohammad, Choquette, Denis, Coupal, Louis, Bykerk, Vivian P, Schieir, Orit, Mosher, Dianne, Marshall, Deborah A, Bernatsky, Sasha, Spencer, Nicole, Richards, Dawn P, Proulx, Laurie, Barber, Claire E H

“…To compare clinical characteristics and treatment of patients with rheumatoid arthritis (RA) across 4 Canadian cohorts. The 4 longitudinal cohorts included the…”
Get full text

Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA) by Gladman, Dafna D, Chandran, Vinod, Rosen, Cheryl F, Rohekar, Sherry, Boyd, Tristan, Eder, Lihi, Rahman, Proton, Dutz, Jan, Chan, Jonathan, Haydey, Richard P, Barac, Snezana, Laliberté, Marie-Claude, Girard, Tanya, Fournier, Pierre-André, Sutton, Mitchell, Pereira, Daniel, Chim, Tina, Coupal, Louis, Choquette, Denis

“…Although patient outcomes in psoriatic arthritis (PsA) have improved with the advent of advanced therapies, there remains a high unmet need to treat residual…”
Get full text

Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary Results from the CHECK-UP Study by Grover, Steven A., Lowensteyn, Ilka, Joseph, Lawrence, Kaouache, Mohammed, Marchand, Sylvie, Coupal, Louis, Boudreau, Ghislain

“…Objectives Hypertension is common among patients with dyslipidemia but is often poorly treated. The objective of this analysis was to evaluate how a decision…”
Get full text

Distinguishing aggressive versus nonaggressive prostate cancer using a novel prognostic proteomics biopsy test, ProMark by Saad, Fred, Shipitsin, Michail, Choudhury, Sibgat, Capela, Teresa, Ernst, Christina, Hurley, Aeron, Small, Clayton, Kaprelyants, Alexander, Hussain, Sadiq, Chang, Hua, Giladi, Eldar, Dunyak, James, Coupal, Louis, Nifong, Thomas, Latour, Mathieu, Berman, David, Blume-Jensen, Peter

“…Abstract only…”
Get full text

Impact of dyslipidemia associated with highly active antiretroviral therapy (HAART) on cardiovascular risk and life expectancy by GROVER, Steven A, COUPAL, Louis, GILMORE, Norbert, MUKHERJEE, Jayanti

“…We investigated the effect of dyslipidemia associated with highly active antiretroviral therapy on cardiovascular risk and life expectancy among patients who…”
Get full text

Treating Osteoarthritis With Cyclooxygenase-2–Specific Inhibitors: What Are the Benefits of Avoiding Blood Pressure Destabilization? by Grover, Steven A, Coupal, Louis, Zowall, Hanna

“…Osteoarthritis and hypertension are highly prevalent among older Americans. Anti-inflammatory medications can destabilize blood pressure control. We estimated…”
Get full text